Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova.
Press Release, October 8, 2020 Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot[TM] platform into a first-line-of-defence for future pandemics.Gothenburg, Sweden, October 8, 2020 Using the proprietary Abiprot[TM] antibody discovery platform, Oblique Therapeutics and collaborators had earlier this year demonstrated that potential epitopes for neutralizing antibodies can be identified
Kiilto is a growing family-owned company from Finland, with a hundred-year history and a vision looking ahead to 2080. We develop, manufacture and market chemical industry solutions in four business areas: construction, industrial bonding, professional hygiene and consumer business. The key principles underlying our operations are environmental leadership, localism, and commitment to the future. We have approximately 1 000 employees, whose wellbeing and expertise are critical to our work for our customers. See our website for more information about us.
As
Kindred Group continues its efforts to reach the target set in 2018 to source 100 per cent renewable electricity by 2023 where we can. Kindred has now aligned its energy targets with the Paris Agreement’s goal of limiting temperature rise to below 2°C and has an ambition to limit it further to below 1.5°C.Kindred Group, an all digital company and thus operating solely online, has aligned its energy targets to the Paris Agreement’s goal of limiting global temperature rise to below 2ºC above pre-industrial levels and pursue efforts to limit it further to 1.5ºC. Targets adopted by companies to
